Drug Trial Radar · NCT04777396
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)
Last checked: Nov 20, 2026Latest source record: Jul 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,840
Actual
Start
May 18, 2021
Primary completion
Sep 16, 2025
Study completion Jan 30, 2026
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Mar 2, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 55 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease. Participants will either get semaglutide or placebo (a "dummy" medicine which does not contain any study medicine) - which treatment participants get is decided by an equal chance. The study will last for up to 173 weeks (about 3 years and 4 months). Participants will have 17 clinic visits and 1 phone call with the study doctor. The study includes various tests and scans. At 10 of the clinic visits participants will have blood samples taken. Participants must have a study partner, who is willing to take part in the study. Women cannot take part if pregnant, breastfeeding or plan to become pregnant during the study period. A cerebrospinal fluid (CSF) sub-study will be performed as a part of the study. The sub-study will be performed on a selection of sites based on their experience with CSF sampling and willingness to participate in this sub-study. The endpoints related to this sub-study are exploratory only.
Conditions
- Early Alzheimer's Disease
Interventions
SemagludtideDrug
Oral semaglutide once-daily, dose gradually increased to 14 mg. The study will last for up to 173 weeks
Placebo (semaglutide)Drug
Oral placebo (semaglutide) once-daily, The study will last for up to 173 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in the Clinical Dementia Rating - Sum of Boxes (CDR-SB) scoreTime frame: From baseline (week 0) to week 104
Locations
447 sites in 37 countries. Site status is shown where the registry gives one.
Banner Alzheimer's Institute
Phoenix, Arizona
Imaging Endpoints
Scottsdale, Arizona
Banner Sun Health Research Institute
Sun City, Arizona
Tucson Neuroscience Research
Tucson, Arizona
Advanced Research Center, Inc.
Anaheim, California
Fullerton Neurology and Headache Center
Fullerton, California
Pacific Research Network
Lemon Grove, California
Torrance Clin Res Inst, Inc.
Lomita, California
ASCLEPES Research Centers,
Long Beach, California
Cedars-Sinai Medical Center
Los Angeles, California
UCLA_Los Angeles
Los Angeles, California
Wr-Pri, Llc
Newport Beach, California
Well Care Medical Center
Panorama City, California
Cedars-Sinai Medical Center
Pasadena, California
Sharp Neurocog Res Ctr
San Diego, California
Syrentis Clinical Research
Santa Ana, California
Calfornia Neurosc Resrch Med
Sherman Oaks, California
Southern California Research LLC
Simi Valley, California
Mountain Neurological Research Center, Inc.
Basalt, Colorado
Denver Neurological Research
Denver, Colorado
Mile High Research Center
Denver, Colorado
Yale University
Fairfield, Connecticut
Topaz Clinical Research
Apopka, Florida
JEM Research Institute
Atlantis, Florida
Visionary Investigators Network
Aventura, Florida
K2 Medical Research - Winter Garden
Clermont, Florida
Brain Matters Research
Delray Beach, Florida
Integrity Clinical Research, LLC
Doral, Florida
Neuropsychiatric Research Cent
Fort Myers, Florida
Finlay Medical Research Group
Greenacres City, Florida
Indago Research & Health Center Inc.
Hialeah, Florida
Hlth Cr Family Rehab & Res Ctr
Hialeah, Florida
Galiz Research
Hialeah, Florida
K2 The Villages
Lady Lake, Florida
K2 Medical Research, Maitland
Maitland, Florida
Hlth Cr Family Rehab & Res Ctr
Miami, Florida
Premier Clin Res Inst, Inc.
Miami, Florida
Premier Clinical Research Institute, Inc.
Miami, Florida
Central Miami Medical Institute
Miami, Florida
Novel Clinical Research Center, LLC
Miami, Florida
Showing 40 of 447 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.